Audit of KI-67 digital image analysis for breast cancer at pathwest QEII

Background: Ki-67 is recognised as an important prognostic and predictive marker in invasive breast carcinoma.1 Controversy regarding Ki-67 assessment and interpretation has limited its clinical application. PathWest QEII previously demonstrated that digital image analysis (DIA) is the most reproducible and efficient method for routine evaluation of Ki-67 in breast carcinoma2 and have been providing Ki-67 as a continuous variable in all breast carcinoma reports since 2013. However, little is reported in the literature regarding quality assurance processes for Ki-67 assessment.